June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Automated central macular fluid volume as a treatment indication for diabetic macular edema
Author Affiliations & Notes
  • Qisheng You
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • kotaro tsuboi
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Yukun Guo
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Christina J Flaxel
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Steven Bailey
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • David Huang
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Yali Jia
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Thomas S Hwang
    Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States
  • Footnotes
    Commercial Relationships   Qisheng You, None; kotaro tsuboi, None; Yukun Guo, None; Christina Flaxel, None; Steven Bailey, OptoVue Inc. (F); David Huang, OptoVue Inc. (F), OptoVue Inc. (I), OptoVue Inc. (P), OptoVue Inc. (R); Yali Jia, OptoVue Inc. (F), OptoVue Inc. (P); Thomas Hwang, None
  • Footnotes
    Support  The study was supported by grants from National Institutes of Health (R01 EY027833, R01 EY024544, DP3 DK104397, P30 EY010572); Unrestricted Departmental Funding Grant and William & Mary Greve Special Scholar Award from Research to Prevent Blindness (New York, NY).
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2451. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Qisheng You, kotaro tsuboi, Yukun Guo, Christina J Flaxel, Steven Bailey, David Huang, Yali Jia, Thomas S Hwang; Automated central macular fluid volume as a treatment indication for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2451.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the value of automated central macular fluid volume (CMFV) as treatment indication for diabetic macular edema (DME).

Methods : In this retrospective observational study, we consecutively enrolled adult diabetic patients who underwent comprehensive clinical examinations, 6x6-mm horizontal 19-line macular structural optical coherence tomography (OCT) raster scans (Spectralis, Heidelberg), and 6x6-mm macular OCT angiography (OCTA) volumetric scans (Avanti, OptoVue) at the baseline enrollment visit. Two retinal specialists reviewed the baseline raster OCT scans independently and diagnosed center-involved DME if intraretinal or subretinal fluid was detected with 1-mm of the foveal center. A third retinal specialist arbitrated any discrepancy. Mean central macular thickness (CMT) within the 1-mm circle was measured on Spectralis OCT scans using the embedded software. A deep-learning algorithm automatically quantified fluid volumes within the central 1-mm circles (CMFV) on the OCTA scans. All patients with DME were treated per standard of care.

Results : We enrolled one eye for each of 215 diabetic patients (98 men) with a mean age of 60 years. Center-involved DME was diagnosed in 93 eyes. The area under the receiver operating characteristic curve (AROC) of CMFV for diagnosis of center-involved DME was 0.907 with a sensitivity of 78.5% at the specificity of 95%. Forty-eight eyes with center-involved DME underwent anti-VEGF injections at the enrollment visit, among whom 34 (71%) eyes fulfilled the DRCR.net treatment criteria (CMT ≥320mm in male or CMT≥305mm in female). Among the 14 treated eyes who were missed according to DRCR.net criteria, 6 (43%) of them would have been diagnosed as center-involved DME, and indicated a treatment, according to the CMFV. Four of these six eyes underwent focal laser treatment previously. Both CMFV and CMT were significantly correlated with best-corrected visual acuity (r=-0.303, P<0.001, and r=-0.339, P<0.001, respectively).

Conclusions : CMFV may be a useful biomarker for DME treatment decisions, particularly for those eyes previously treated with focal laser. A cohort study is indicated to assess the treatment response of CMFV.

This is a 2021 ARVO Annual Meeting abstract.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×